Multiple Sclerosis Therapeutics market worldwide is projected to grow by US$4 Billion, driven by a compounded growth of 2. 6%. Beta Interferon, one of the segments analyzed and sized in this study, displays the potential to grow at over 2.

New York, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Multiple Sclerosis Therapeutics Industry" - https://www.reportlinker.com/p05818011/?utm_source=GNW
7%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.8 Billion by the year 2025, Beta Interferon will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 2.1% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$151.7 Million to the region’s size and clout in the next 5 to 6 years. Over US$116.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Beta Interferon will reach a market size of US$162.3 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 4.2% over the next couple of years and add approximately US$1.1 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include among others, AbbVie, Inc.; Bayer AG; Biogen, Inc.; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.


Read the full report: https://www.reportlinker.com/p05818011/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Multiple Sclerosis Therapeutics Competitor Market Share
Scenario Worldwide (in %): 2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: Multiple Sclerosis Therapeutics Global Market
Estimates and Forecasts in US$ Million by Region/Country:
2018-2025
Table 2: Multiple Sclerosis Therapeutics Global Retrospective
Market Scenario in US$ Million by Region/Country: 2009-2017
Table 3: Multiple Sclerosis Therapeutics Market Share Shift
across Key Geographies Worldwide: 2009 VS 2019 VS 2025
Table 4: Beta Interferon (Drug Class) World Market by
Region/Country in US$ Million: 2018 to 2025
Table 5: Beta Interferon (Drug Class) Historic Market Analysis
by Region/Country in US$ Million: 2009 to 2017
Table 6: Beta Interferon (Drug Class) Market Share Breakdown of
Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
Table 7: Corticosteroids (Drug Class) Potential Growth Markets
Worldwide in US$ Million: 2018 to 2025
Table 8: Corticosteroids (Drug Class) Historic Market
Perspective by Region/Country in US$ Million: 2009 to 2017
Table 9: Corticosteroids (Drug Class) Market Sales Breakdown by
Region/Country in Percentage: 2009 VS 2019 VS 2025
Table 10: Monoclonal Antibodies (Drug Class) Geographic Market
Spread Worldwide in US$ Million: 2018 to 2025
Table 11: Monoclonal Antibodies (Drug Class) Region Wise
Breakdown of Global Historic Demand in US$ Million: 2009 to
2017
Table 12: Monoclonal Antibodies (Drug Class) Market Share
Distribution in Percentage by Region/Country: 2009 VS 2019 VS
2025
Table 13: Antineoplastic Agents (Drug Class) World Market
Estimates and Forecasts by Region/Country in US$ Million: 2018
to 2025
Table 14: Antineoplastic Agents (Drug Class) Market Historic
Review by Region/Country in US$ Million: 2009 to 2017
Table 15: Antineoplastic Agents (Drug Class) Market Share
Breakdown by Region/Country: 2009 VS 2019 VS 2025
Table 16: Other Drug Class (Drug Class) World Market by
Region/Country in US$ Million: 2018 to 2025
Table 17: Other Drug Class (Drug Class) Historic Market
Analysis by Region/Country in US$ Million: 2009 to 2017
Table 18: Other Drug Class (Drug Class) Market Share
Distribution in Percentage by Region/Country: 2009 VS 2019 VS
2025
Table 19: Oral (Therapeutics) World Market Estimates and
Forecasts in US$ Million by Region/Country: 2018 to 2025
Table 20: Oral (Therapeutics) Market Worldwide Historic Review
by Region/Country in US$ Million: 2009 to 2017
Table 21: Oral (Therapeutics) Market Percentage Share
Distribution by Region/Country: 2009 VS 2019 VS 2025
Table 22: Injection (Therapeutics) Market Opportunity Analysis
Worldwide in US$ Million by Region/Country: 2018 to 2025
Table 23: Injection (Therapeutics) Global Historic Demand in
US$ Million by Region/Country: 2009 to 2017
Table 24: Injection (Therapeutics) Market Share Distribution in
Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Multiple Sclerosis Therapeutics Market Share (in %) by
Company: 2019 & 2025
Table 25: United States Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Drug Class: 2018 to
2025
Table 26: Multiple Sclerosis Therapeutics Market in the United
States by Drug Class: A Historic Review in US$ Million for
2009-2017
Table 27: United States Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 28: United States Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Therapeutics: 2018
to 2025
Table 29: Multiple Sclerosis Therapeutics Market in the United
States by Therapeutics: A Historic Review in US$ Million for
2009-2017
Table 30: United States Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
CANADA
Table 31: Canadian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018 to
2025
Table 32: Canadian Multiple Sclerosis Therapeutics Historic
Market Review by Drug Class in US$ Million: 2009-2017
Table 33: Multiple Sclerosis Therapeutics Market in Canada:
Percentage Share Breakdown of Sales by Drug Class for 2009,
2019, and 2025
Table 34: Canadian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics: 2018 to
2025
Table 35: Canadian Multiple Sclerosis Therapeutics Historic
Market Review by Therapeutics in US$ Million: 2009-2017
Table 36: Multiple Sclerosis Therapeutics Market in Canada:
Percentage Share Breakdown of Sales by Therapeutics for 2009,
2019, and 2025
JAPAN
Table 37: Japanese Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by Drug
Class for the Period 2018-2025
Table 38: Multiple Sclerosis Therapeutics Market in Japan:
Historic Sales Analysis in US$ Million by Drug Class for the
Period 2009-2017
Table 39: Japanese Multiple Sclerosis Therapeutics Market Share
Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 40: Japanese Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by
Therapeutics for the Period 2018-2025
Table 41: Multiple Sclerosis Therapeutics Market in Japan:
Historic Sales Analysis in US$ Million by Therapeutics for the
Period 2009-2017
Table 42: Japanese Multiple Sclerosis Therapeutics Market Share
Analysis by Therapeutics: 2009 VS 2019 VS 2025
CHINA
Table 43: Chinese Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Drug Class for the Period 2018-2025
Table 44: Multiple Sclerosis Therapeutics Historic Market
Analysis in China in US$ Million by Drug Class: 2009-2017
Table 45: Chinese Multiple Sclerosis Therapeutics Market by
Drug Class: Percentage Breakdown of Sales for 2009, 2019, and
2025
Table 46: Chinese Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Therapeutics for the Period
2018-2025
Table 47: Multiple Sclerosis Therapeutics Historic Market
Analysis in China in US$ Million by Therapeutics: 2009-2017
Table 48: Chinese Multiple Sclerosis Therapeutics Market by
Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and
2025
EUROPE
Market Facts & Figures
European Multiple Sclerosis Therapeutics Market: Competitor
Market Share Scenario (in %) for 2019 & 2025
Table 49: European Multiple Sclerosis Therapeutics Market
Demand Scenario in US$ Million by Region/Country: 2018-2025
Table 50: Multiple Sclerosis Therapeutics Market in Europe: A
Historic Market Perspective in US$ Million by Region/Country
for the Period 2009-2017
Table 51: European Multiple Sclerosis Therapeutics Market Share
Shift by Region/Country: 2009 VS 2019 VS 2025
Table 52: European Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 53: Multiple Sclerosis Therapeutics Market in Europe in
US$ Million by Drug Class: A Historic Review for the Period
2009-2017
Table 54: European Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 55: European Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 56: Multiple Sclerosis Therapeutics Market in Europe in
US$ Million by Therapeutics: A Historic Review for the Period
2009-2017
Table 57: European Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
FRANCE
Table 58: Multiple Sclerosis Therapeutics Market in France by
Drug Class: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 59: French Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Drug Class: 2009-2017
Table 60: French Multiple Sclerosis Therapeutics Market Share
Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 61: Multiple Sclerosis Therapeutics Market in France by
Therapeutics: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 62: French Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Therapeutics: 2009-2017
Table 63: French Multiple Sclerosis Therapeutics Market Share
Analysis by Therapeutics: 2009 VS 2019 VS 2025
GERMANY
Table 64: Multiple Sclerosis Therapeutics Market in Germany:
Recent Past, Current and Future Analysis in US$ Million by Drug
Class for the Period 2018-2025
Table 65: German Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Drug Class: 2009-2017
Table 66: German Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 67: Multiple Sclerosis Therapeutics Market in Germany:
Recent Past, Current and Future Analysis in US$ Million by
Therapeutics for the Period 2018-2025
Table 68: German Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Therapeutics: 2009-2017
Table 69: German Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
ITALY
Table 70: Italian Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Drug Class for the Period 2018-2025
Table 71: Multiple Sclerosis Therapeutics Historic Market
Analysis in Italy in US$ Million by Drug Class: 2009-2017
Table 72: Italian Multiple Sclerosis Therapeutics Market by
Drug Class: Percentage Breakdown of Sales for 2009, 2019, and
2025
Table 73: Italian Multiple Sclerosis Therapeutics Market Growth
Prospects in US$ Million by Therapeutics for the Period
2018-2025
Table 74: Multiple Sclerosis Therapeutics Historic Market
Analysis in Italy in US$ Million by Therapeutics: 2009-2017
Table 75: Italian Multiple Sclerosis Therapeutics Market by
Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and
2025
UNITED KINGDOM
Table 76: United Kingdom Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Drug Class for the Period 2018-2025
Table 77: Multiple Sclerosis Therapeutics Market in the United
Kingdom: Historic Sales Analysis in US$ Million by Drug Class
for the Period 2009-2017
Table 78: United Kingdom Multiple Sclerosis Therapeutics Market
Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 79: United Kingdom Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Therapeutics for the Period 2018-2025
Table 80: Multiple Sclerosis Therapeutics Market in the United
Kingdom: Historic Sales Analysis in US$ Million by Therapeutics
for the Period 2009-2017
Table 81: United Kingdom Multiple Sclerosis Therapeutics Market
Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
SPAIN
Table 82: Spanish Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018 to
2025
Table 83: Spanish Multiple Sclerosis Therapeutics Historic
Market Review by Drug Class in US$ Million: 2009-2017
Table 84: Multiple Sclerosis Therapeutics Market in Spain:
Percentage Share Breakdown of Sales by Drug Class for 2009,
2019, and 2025
Table 85: Spanish Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics: 2018 to
2025
Table 86: Spanish Multiple Sclerosis Therapeutics Historic
Market Review by Therapeutics in US$ Million: 2009-2017
Table 87: Multiple Sclerosis Therapeutics Market in Spain:
Percentage Share Breakdown of Sales by Therapeutics for 2009,
2019, and 2025
RUSSIA
Table 88: Russian Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Drug Class: 2018 to
2025
Table 89: Multiple Sclerosis Therapeutics Market in Russia by
Drug Class: A Historic Review in US$ Million for 2009-2017
Table 90: Russian Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 91: Russian Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Therapeutics: 2018
to 2025
Table 92: Multiple Sclerosis Therapeutics Market in Russia by
Therapeutics: A Historic Review in US$ Million for 2009-2017
Table 93: Russian Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
REST OF EUROPE
Table 94: Rest of Europe Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 95: Multiple Sclerosis Therapeutics Market in Rest of
Europe in US$ Million by Drug Class: A Historic Review for the
Period 2009-2017
Table 96: Rest of Europe Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 97: Rest of Europe Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 98: Multiple Sclerosis Therapeutics Market in Rest of
Europe in US$ Million by Therapeutics: A Historic Review for
the Period 2009-2017
Table 99: Rest of Europe Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
ASIA-PACIFIC
Table 100: Asia-Pacific Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Region/Country:
2018-2025
Table 101: Multiple Sclerosis Therapeutics Market in
Asia-Pacific: Historic Market Analysis in US$ Million by
Region/Country for the Period 2009-2017
Table 102: Asia-Pacific Multiple Sclerosis Therapeutics Market
Share Analysis by Region/Country: 2009 VS 2019 VS 2025
Table 103: Multiple Sclerosis Therapeutics Market in
Asia-Pacific by Drug Class: Estimates and Projections in US$
Million for the Period 2018-2025
Table 104: Asia-Pacific Multiple Sclerosis Therapeutics
Historic Market Scenario in US$ Million by Drug Class:
2009-2017
Table 105: Asia-Pacific Multiple Sclerosis Therapeutics Market
Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 106: Multiple Sclerosis Therapeutics Market in
Asia-Pacific by Therapeutics: Estimates and Projections in US$
Million for the Period 2018-2025
Table 107: Asia-Pacific Multiple Sclerosis Therapeutics
Historic Market Scenario in US$ Million by Therapeutics:
2009-2017
Table 108: Asia-Pacific Multiple Sclerosis Therapeutics Market
Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
AUSTRALIA
Table 109: Multiple Sclerosis Therapeutics Market in Australia:
Recent Past, Current and Future Analysis in US$ Million by Drug
Class for the Period 2018-2025
Table 110: Australian Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Drug Class: 2009-2017
Table 111: Australian Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 112: Multiple Sclerosis Therapeutics Market in Australia:
Recent Past, Current and Future Analysis in US$ Million by
Therapeutics for the Period 2018-2025
Table 113: Australian Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Therapeutics: 2009-2017
Table 114: Australian Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
INDIA
Table 115: Indian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018 to
2025
Table 116: Indian Multiple Sclerosis Therapeutics Historic
Market Review by Drug Class in US$ Million: 2009-2017
Table 117: Multiple Sclerosis Therapeutics Market in India:
Percentage Share Breakdown of Sales by Drug Class for 2009,
2019, and 2025
Table 118: Indian Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics: 2018 to
2025
Table 119: Indian Multiple Sclerosis Therapeutics Historic
Market Review by Therapeutics in US$ Million: 2009-2017
Table 120: Multiple Sclerosis Therapeutics Market in India:
Percentage Share Breakdown of Sales by Therapeutics for 2009,
2019, and 2025
SOUTH KOREA
Table 121: Multiple Sclerosis Therapeutics Market in South
Korea: Recent Past, Current and Future Analysis in US$ Million
by Drug Class for the Period 2018-2025
Table 122: South Korean Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Drug Class:
2009-2017
Table 123: Multiple Sclerosis Therapeutics Market Share
Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025
Table 124: Multiple Sclerosis Therapeutics Market in South
Korea: Recent Past, Current and Future Analysis in US$ Million
by Therapeutics for the Period 2018-2025
Table 125: South Korean Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Therapeutics:
2009-2017
Table 126: Multiple Sclerosis Therapeutics Market Share
Distribution in South Korea by Therapeutics: 2009 VS 2019 VS
2025
REST OF ASIA-PACIFIC
Table 127: Rest of Asia-Pacific Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Drug Class for the Period 2018-2025
Table 128: Multiple Sclerosis Therapeutics Market in Rest of
Asia-Pacific: Historic Sales Analysis in US$ Million by Drug
Class for the Period 2009-2017
Table 129: Rest of Asia-Pacific Multiple Sclerosis Therapeutics
Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 130: Rest of Asia-Pacific Market for Multiple Sclerosis
Therapeutics: Annual Sales Estimates and Projections in US$
Million by Therapeutics for the Period 2018-2025
Table 131: Multiple Sclerosis Therapeutics Market in Rest of
Asia-Pacific: Historic Sales Analysis in US$ Million by
Therapeutics for the Period 2009-2017
Table 132: Rest of Asia-Pacific Multiple Sclerosis Therapeutics
Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
LATIN AMERICA
Table 133: Latin American Multiple Sclerosis Therapeutics
Market Trends by Region/Country in US$ Million: 2018-2025
Table 134: Multiple Sclerosis Therapeutics Market in Latin
America in US$ Million by Region/Country: A Historic
Perspective for the Period 2009-2017
Table 135: Latin American Multiple Sclerosis Therapeutics
Market Percentage Breakdown of Sales by Region/Country: 2009,
2019, and 2025
Table 136: Latin American Multiple Sclerosis Therapeutics
Market Growth Prospects in US$ Million by Drug Class for the
Period 2018-2025
Table 137: Multiple Sclerosis Therapeutics Historic Market
Analysis in Latin America in US$ Million by Drug Class:
2009-2017
Table 138: Latin American Multiple Sclerosis Therapeutics
Market by Drug Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
Table 139: Latin American Multiple Sclerosis Therapeutics
Market Growth Prospects in US$ Million by Therapeutics for the
Period 2018-2025
Table 140: Multiple Sclerosis Therapeutics Historic Market
Analysis in Latin America in US$ Million by Therapeutics:
2009-2017
Table 141: Latin American Multiple Sclerosis Therapeutics
Market by Therapeutics: Percentage Breakdown of Sales for
2009, 2019, and 2025
ARGENTINA
Table 142: Argentinean Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 143: Multiple Sclerosis Therapeutics Market in Argentina
in US$ Million by Drug Class: A Historic Review for the Period
2009-2017
Table 144: Argentinean Multiple Sclerosis Therapeutics Market
Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 145: Argentinean Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 146: Multiple Sclerosis Therapeutics Market in Argentina
in US$ Million by Therapeutics: A Historic Review for the
Period 2009-2017
Table 147: Argentinean Multiple Sclerosis Therapeutics Market
Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
BRAZIL
Table 148: Multiple Sclerosis Therapeutics Market in Brazil by
Drug Class: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 149: Brazilian Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Drug Class: 2009-2017
Table 150: Brazilian Multiple Sclerosis Therapeutics Market
Share Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 151: Multiple Sclerosis Therapeutics Market in Brazil by
Therapeutics: Estimates and Projections in US$ Million for the
Period 2018-2025
Table 152: Brazilian Multiple Sclerosis Therapeutics Historic
Market Scenario in US$ Million by Therapeutics: 2009-2017
Table 153: Brazilian Multiple Sclerosis Therapeutics Market
Share Analysis by Therapeutics: 2009 VS 2019 VS 2025
MEXICO
Table 154: Multiple Sclerosis Therapeutics Market in Mexico:
Recent Past, Current and Future Analysis in US$ Million by Drug
Class for the Period 2018-2025
Table 155: Mexican Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Drug Class: 2009-2017
Table 156: Mexican Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 157: Multiple Sclerosis Therapeutics Market in Mexico:
Recent Past, Current and Future Analysis in US$ Million by
Therapeutics for the Period 2018-2025
Table 158: Mexican Multiple Sclerosis Therapeutics Historic
Market Analysis in US$ Million by Therapeutics: 2009-2017
Table 159: Mexican Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
Table 160: Rest of Latin America Multiple Sclerosis
Therapeutics Market Estimates and Projections in US$ Million by
Drug Class: 2018 to 2025
Table 161: Multiple Sclerosis Therapeutics Market in Rest of
Latin America by Drug Class: A Historic Review in US$ Million
for 2009-2017
Table 162: Rest of Latin America Multiple Sclerosis
Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019
VS 2025
Table 163: Rest of Latin America Multiple Sclerosis
Therapeutics Market Estimates and Projections in US$ Million by
Therapeutics: 2018 to 2025
Table 164: Multiple Sclerosis Therapeutics Market in Rest of
Latin America by Therapeutics: A Historic Review in US$ Million
for 2009-2017
Table 165: Rest of Latin America Multiple Sclerosis
Therapeutics Market Share Breakdown by Therapeutics: 2009 VS
2019 VS 2025
MIDDLE EAST
Table 166: The Middle East Multiple Sclerosis Therapeutics
Market Estimates and Forecasts in US$ Million by
Region/Country: 2018-2025
Table 167: Multiple Sclerosis Therapeutics Market in the Middle
East by Region/Country in US$ Million: 2009-2017
Table 168: The Middle East Multiple Sclerosis Therapeutics
Market Share Breakdown by Region/Country: 2009, 2019, and 2025
Table 169: The Middle East Multiple Sclerosis Therapeutics
Market Estimates and Forecasts in US$ Million by Drug Class:
2018 to 2025
Table 170: The Middle East Multiple Sclerosis Therapeutics
Historic Market by Drug Class in US$ Million: 2009-2017
Table 171: Multiple Sclerosis Therapeutics Market in the Middle
East: Percentage Share Breakdown of Sales by Drug Class for
2009, 2019, and 2025
Table 172: The Middle East Multiple Sclerosis Therapeutics
Market Estimates and Forecasts in US$ Million by Therapeutics:
2018 to 2025
Table 173: The Middle East Multiple Sclerosis Therapeutics
Historic Market by Therapeutics in US$ Million: 2009-2017
Table 174: Multiple Sclerosis Therapeutics Market in the Middle
East: Percentage Share Breakdown of Sales by Therapeutics for
2009, 2019, and 2025
IRAN
Table 175: Iranian Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by Drug
Class for the Period 2018-2025
Table 176: Multiple Sclerosis Therapeutics Market in Iran:
Historic Sales Analysis in US$ Million by Drug Class for the
Period 2009-2017
Table 177: Iranian Multiple Sclerosis Therapeutics Market Share
Analysis by Drug Class: 2009 VS 2019 VS 2025
Table 178: Iranian Market for Multiple Sclerosis Therapeutics:
Annual Sales Estimates and Projections in US$ Million by
Therapeutics for the Period 2018-2025
Table 179: Multiple Sclerosis Therapeutics Market in Iran:
Historic Sales Analysis in US$ Million by Therapeutics for the
Period 2009-2017
Table 180: Iranian Multiple Sclerosis Therapeutics Market Share
Analysis by Therapeutics: 2009 VS 2019 VS 2025
ISRAEL
Table 181: Israeli Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
Table 182: Multiple Sclerosis Therapeutics Market in Israel in
US$ Million by Drug Class: A Historic Review for the Period
2009-2017
Table 183: Israeli Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 184: Israeli Multiple Sclerosis Therapeutics Market
Estimates and Forecasts in US$ Million by Therapeutics:
2018-2025
Table 185: Multiple Sclerosis Therapeutics Market in Israel in
US$ Million by Therapeutics: A Historic Review for the Period
2009-2017
Table 186: Israeli Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025
SAUDI ARABIA
Table 187: Saudi Arabian Multiple Sclerosis Therapeutics Market
Growth Prospects in US$ Million by Drug Class for the Period
2018-2025
Table 188: Multiple Sclerosis Therapeutics Historic Market
Analysis in Saudi Arabia in US$ Million by Drug Class:
2009-2017
Table 189: Saudi Arabian Multiple Sclerosis Therapeutics Market
by Drug Class: Percentage Breakdown of Sales for 2009, 2019,
and 2025
Table 190: Saudi Arabian Multiple Sclerosis Therapeutics Market
Growth Prospects in US$ Million by Therapeutics for the Period
2018-2025
Table 191: Multiple Sclerosis Therapeutics Historic Market
Analysis in Saudi Arabia in US$ Million by Therapeutics:
2009-2017
Table 192: Saudi Arabian Multiple Sclerosis Therapeutics Market
by Therapeutics: Percentage Breakdown of Sales for 2009, 2019,
and 2025
UNITED ARAB EMIRATES
Table 193: Multiple Sclerosis Therapeutics Market in the United
Arab Emirates: Recent Past, Current and Future Analysis in US$
Million by Drug Class for the Period 2018-2025
Table 194: United Arab Emirates Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Drug Class:
2009-2017
Table 195: Multiple Sclerosis Therapeutics Market Share
Distribution in United Arab Emirates by Drug Class: 2009 VS
2019 VS 2025
Table 196: Multiple Sclerosis Therapeutics Market in the United
Arab Emirates: Recent Past, Current and Future Analysis in US$
Million by Therapeutics for the Period 2018-2025
Table 197: United Arab Emirates Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Therapeutics:
2009-2017
Table 198: Multiple Sclerosis Therapeutics Market Share
Distribution in United Arab Emirates by Therapeutics: 2009 VS
2019 VS 2025
REST OF MIDDLE EAST
Table 199: Multiple Sclerosis Therapeutics Market in Rest of
Middle East: Recent Past, Current and Future Analysis in US$
Million by Drug Class for the Period 2018-2025
Table 200: Rest of Middle East Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Drug Class:
2009-2017
Table 201: Rest of Middle East Multiple Sclerosis Therapeutics
Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 202: Multiple Sclerosis Therapeutics Market in Rest of
Middle East: Recent Past, Current and Future Analysis in US$
Million by Therapeutics for the Period 2018-2025
Table 203: Rest of Middle East Multiple Sclerosis Therapeutics
Historic Market Analysis in US$ Million by Therapeutics:
2009-2017
Table 204: Rest of Middle East Multiple Sclerosis Therapeutics
Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025
AFRICA
Table 205: African Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Drug Class: 2018 to
2025
Table 206: Multiple Sclerosis Therapeutics Market in Africa by
Drug Class: A Historic Review in US$ Million for 2009-2017
Table 207: African Multiple Sclerosis Therapeutics Market Share
Breakdown by Drug Class: 2009 VS 2019 VS 2025
Table 208: African Multiple Sclerosis Therapeutics Market
Estimates and Projections in US$ Million by Therapeutics: 2018
to 2025
Table 209: Multiple Sclerosis Therapeutics Market in Africa by
Therapeutics: A Historic Review in US$ Million for 2009-2017
Table 210: African Multiple Sclerosis Therapeutics Market Share
Breakdown by Therapeutics: 2009 VS 2019 VS 2025

IV. COMPETITION

ABBVIE
BAYER AG
BIOGEN
MERCK & CO., INC.
NOVARTIS INTERNATIONAL AG
PFIZER
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES

V. CURATED RESEARCH
Read the full report: https://www.reportlinker.com/p05818011/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001